258 related articles for article (PubMed ID: 30762246)
21. Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection.
Tavakolpour S; Soori T; Noormohammadpour P; Balighi K; Mahmoudi H; Daneshpazhooh M
Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633752
[TBL] [Abstract][Full Text] [Related]
22. Pemphigus foliaceus with circinated plaques and neutrophil pustules.
Méndez-Flores S; Avalos-Diaz E; Dominguez-Cherit J; Saeb-Lima M; Esquivel-Pedraza L
J Cutan Pathol; 2016 Nov; 43(11):1062-1066. PubMed ID: 27514363
[TBL] [Abstract][Full Text] [Related]
23. Childhood pemphigus vulgaris successfully treated with rituximab.
Kanwar AJ; Sawatkar GU; Vinay K; Hashimoto T
Indian J Dermatol Venereol Leprol; 2012; 78(5):632-4. PubMed ID: 22960821
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
25. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab.
Wei KC; Wang YH; Wang WH; Chen W
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e350-e351. PubMed ID: 28129481
[No Abstract] [Full Text] [Related]
26. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of recalcitrant pemphigus foliaceus with rituximab.
Serrão VV; Martins A; Páris FR; Lopes MP
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):768-70. PubMed ID: 18482042
[No Abstract] [Full Text] [Related]
29. Reactivation of pemphigus by varicella zoster virus after anti-CD20 treatment.
Douard PA; Delaumenie S; Pittoni J; Assikar S; Matei I; Prudhomme R; Audevard D; Bédane C
Int J Dermatol; 2020 Mar; 59(3):e52-e53. PubMed ID: 31840226
[No Abstract] [Full Text] [Related]
30. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
31. [RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER].
Mimouni D; Baum S
Harefuah; 2020 Jan; 159(1):31-33. PubMed ID: 31930805
[TBL] [Abstract][Full Text] [Related]
32. Nasal, pharyngeal, and laryngeal pemphigus vulgaris successfully treated with rituximab.
Sami N
Ear Nose Throat J; 2017; 96(4-5):E35-E38. PubMed ID: 28489243
[TBL] [Abstract][Full Text] [Related]
33. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
35. [Rituximab as treatment for refractory pemphigus in Mexican patients].
Cruz-Meza S; Ruiz-Arriaga LF; Barrón-Tapia MT; Estrada-Aguilar L
Rev Alerg Mex; 2021; 68(1):7-11. PubMed ID: 34148324
[TBL] [Abstract][Full Text] [Related]
36. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
[TBL] [Abstract][Full Text] [Related]
37. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
Greenblatt DT; Benton EC; Groves RW; Setterfield JF
Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
[TBL] [Abstract][Full Text] [Related]
38. [Unexpected positive outcome following rituximab treatment in a patient with pemphigus vegetans resistant to conventional therapies: a case report].
Barbach Y; Baybay H; Mrabat S; Chaouche M; Elloudi S; Mernissi FZ
Pan Afr Med J; 2019; 32():101. PubMed ID: 31223391
[TBL] [Abstract][Full Text] [Related]
39. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab.
Balighi K; Sakhi RS; Daneshpazhooh M; Mahmoudi H; Teimourpour A; Tavakolpour S
Dermatol Ther; 2018 Nov; 31(6):e12671. PubMed ID: 30246907
[No Abstract] [Full Text] [Related]
40. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab.
Albers LN; Liu Y; Bo N; Swerlick RA; Feldman RJ
J Am Acad Dermatol; 2017 Dec; 77(6):1074-1082. PubMed ID: 28927663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
